The 4Kscore combines four prostate-specific biomarkers with clinical information to provide men with an accurate and personalized measure of their risk for aggressive prostate cancer. The 4Kscore can be used prior to biopsy, or after a negative biopsy, and can predict the likelihood of cancer spreading to other parts of the body in the next 20 years.
“We’re being told by many government bodies and regulatory agencies that we shouldn’t even screen men for prostate cancer, yet we’ve seen the mortality rate for prostate cancer fall steadily over the last two decades with PSA screening. In my opinion, the response to the challenge we’re facing in accurate detection of prostate cancer is not to abandon PSA testing altogether, but to learn how to test smarter, how to screen patients with PSA smarter and more accurately. I think the 4Kscore Test is a great tool for helping us do that.”Peter Scardino, M.D. Chairman, Department of Surgery, Memorial Sloan-Kettering Cancer Center*
*Disclosure: Dr. Scardino is an inventor of the 4Kscore Test and is involved in its commercial development. Dr. Scardino is a paid consultant to OPKO Health, Inc., the company to which the 4Kscore Test is licensed.
“Prostate biopsy is a very anxiety-provoking procedure. Men are very fearful about one specific question: Do I have prostate cancer? The 4Kscore Test helps Urologists decide when a prostate biopsy is an appropriate next plan of action.”Stephen Zappala, M.D. Assistant Clinical Professor of Urology, Tufts University Fellow-American College of Surgeons Diplomat of the American Board of Urology